What is RPRX's health score?

Royalty Pharma plc (RPRX) has a TradeApes health score of 52 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is RPRX's estimated fair value?

Based on our 5-year discounted cash flow model, Royalty Pharma plc's estimated fair value is $63.03 per share, representing a 12.8% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is RPRX undervalued or overvalued?

Our model currently rates RPRX as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for RPRX... Refresh in a moment for the full analysis.

Royalty Pharma plc (RPRX)

Healthcare Fair Value medium mixed

$55.87

Updated: 2026-06-06

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

50 Mixed

Relative Value

63 Healthy

Capital Allocation

35 Weak

Risk

70 Healthy

Est. Fair Value $63.03

DCF Upside +12.8%

Sector Rank #320 of 6562

Key Findings

+ High FCF yield — above 7%, strong cash return relative to price paid

Unlock Full Report →

− Very high leverage — net debt/EBITDA above 5×

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.